Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author holds a long position in SDGR.
← Back to Free Index

SDGR

Analysis as of: 2026-03-07
Schrödinger, Inc.
Schrödinger sells computational chemistry and discovery workflow software and uses that platform to generate partnered and proprietary drug programs.
ai biotech enterprise healthcare software
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Workflow depth can unlock a measured rerating
The opportunity is a cleaner, more valuable business mix rather than a moonshot. If hosted software deepens customer embed and partnered programs monetize without heavy burn, the equity can compound at a strong rate from a reset base.

Analysis

Thesis
The realistic bull case is not that Schrödinger becomes the foundation model winner in drug discovery; it is that AI makes molecular ideation cheap while Schrödinger becomes the trusted, hosted workflow and verification layer that large pharma still pays for, with milestone and royalty upside layered on top without restoring heavy internal clinical burn.
Last Economy Alignment
Cheaper AI expands demand for computational discovery, and Schrödinger can capture it if value shifts from seats to governed workflow, verification, and partner-facing execution rather than standalone modeling licenses.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
6.0x (from 5 most recent analyses)
Reasoning
The upside comes from three layers working together: steady growth in core software, better revenue quality as hosted contracts replace upfront licenses, and selective milestone or royalty monetization from partnered programs. That mix can make the business look less like a lumpy tools vendor and more like a sticky discovery operating layer. I only underwrite partial success on new platform products and external partnering, not a heroic pipeline outcome.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The main risk is not technology failure; it is value-capture failure. Schrödinger must prove that as AI makes molecule design cheaper, customers still pay for its governed workflow, hosted execution, and verification layer rather than piecing together cheaper internal or open alternatives. The second risk is that therapeutics upside is now more dependent on partner appetite and deal timing than on internal ambition alone.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.47
They own a real workflow layer for drug discovery, and AI makes that layer more useful if teams need one trusted place to run, verify, and share work. The risk is that pharma builds its own stack or cheap AI tools turn Schrödinger’s modeling into just another feature.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$22.00
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case